New migraine drug shows promise in Real-World study
NCT ID NCT05709106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well the migraine medication Rimegepant works in real-world settings. Researchers followed 173 adults with migraines who took the drug as needed for acute attacks or long-term prevention. Participants recorded pain levels at several time points after dosing and tracked monthly migraine days to assess effectiveness and safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine
Boao, Hainan, 571434, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?